Clausena anisata-mediated protection against lipopolysaccharide-induced acute lung injury in mice

Jeon,Chan-Mi; Shin,In-Sik; Shin,Na-Rae; Hong,Ju-Mi; Kwon,Ok-Kyoung; Kim,Jung-Hee; Oh,Sei-Ryang; Bach,Tran-The; Hai,Do-Van; Quang,Bui-Hong; Choi,Sang-Ho; Lee,Joongku; Myung,Pyung-Keun; Ahn,Kyung-Seop

doi:10.3892/ijmm.2016.2515

Clausena anisata-mediated protection against lipopolysaccharide-induced acute lung injury in mice

Authors:
- Chan-Mi Jeon
- In-Sik Shin
- Na-Rae Shin
- Ju-Mi Hong
- Ok-Kyoung Kwon
- Jung-Hee Kim
- Sei-Ryang Oh
- Tran-The Bach
- Do-Van Hai
- Bui-Hong Quang
- Sang-Ho Choi
- Joongku Lee
- Pyung-Keun Myung
- Kyung-Seop Ahn
View Affiliations

Affiliations: Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon‑gu, Cheongju‑si, Chungcheongbuk‑do 28116, Republic of Korea, IEBR, Vietnam Academy of Science and Technology (VAST), Cay Giay, Ha Noi, Vietnam, International Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Yuseong‑gu, Daejeon 34141, Republic of Korea, College of Pharmacy, Chungnam National University, Yuseong‑gu, Daejeon, Chungcheongnam‑do 34134, Republic of Korea
Published online on: March 3, 2016 https://doi.org/10.3892/ijmm.2016.2515
Pages: 1091-1098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clausena anisata (Willd.) Hook.f. ex Benth. (CA), which is widely used in traditional medicine, reportedly exerts antitumor, anti-inflammatory and other important therapeutic effects. The aim of the present study was to investigate the potential therapeutic effects of CA in a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI) and in LPS-stimulated RAW 264.7 cells. Male C57BL/6 mice were administered treatments for 3 days by oral gavage. On day 3, the mice were instilled intranasally with LPS or PBS followed 3 h later by oral CA (30 mg/kg) or vehicle administration. In vitro, CA decreased nitric oxide (NO) production and pro-inflammatory cytokines, such as interleukin (IL)-6 and prostaglandin E2 (PGE2), in LPS-stimulated RAW 264.7 cells. CA also reduced the expression of pro-inflammatory mediators, such as cyclooxygenase-2. In vivo, CA administration significantly reduced inflammatory cell numbers in the bronchoalveolar lavage fluid (BALF) and suppressed pro-inflammatory cytokine levels, including tumor necrosis factor-α (TNF-α), IL-6, and IL-1β, as well as reactive oxygen species production in the BALF. CA also effectively reduced airway inflammation in mouse lung tissue of an LPS-induced ALI mouse model, in addition to decreasing inhibitor κB (IκB) and nuclear factor-κB (NF-κB) p65 phosphorylation. Taken together, the findings demonstrated that CA inhibited inflammatory responses in a mouse model of LPS-induced ALI and in LPS-stimulated RAW 264.7 cells. Thus, CA is a potential candidate for development as an adjunctive treatment for inflammatory disorders, such as ALI.

View Figures

View References

1	Basu RK, Chawla LS, Wheeler DS and Goldstein SL: Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. Pediatr Nephrol. 27:1067–1078. 2012. View Article : Google Scholar :
2	Atabai K and Matthay MA: The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax. 57:452–458. 2002. View Article : Google Scholar : PubMed/NCBI
3	Raghavendran K and Napolitano LM: Definition of ALI/ARDS. Crit Care Clin. 27:429–437. 2011. View Article : Google Scholar : PubMed/NCBI
4	Chignard M and Balloy V: Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol. 279:L1083–L1090. 2000.PubMed/NCBI
5	Shang Y, Li X, Prasad PV, Xu S, Yao S, Liu D, Yuan S and Feng D: Erythropoietin attenuates lung injury in lipopolysaccharide treated rats. J Surg Res. 155:104–110. 2009. View Article : Google Scholar : PubMed/NCBI
6	Diaz JV, Brower R, Calfee CS and Matthay MA: Therapeutic strategies for severe acute lung injury. Crit Care Med. 38:1644–1650. 2010. View Article : Google Scholar : PubMed/NCBI
7	Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, et al: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 133:235–249. 2008. View Article : Google Scholar : PubMed/NCBI
8	Zambon M and Vincent JL: Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 133:1120–1127. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kitamura Y, Hashimoto S, Mizuta N, Kobayashi A, Kooguchi K, Fujiwara I and Nakajima H: Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. Am J Respir Crit Care Med. 163:762–769. 2001. View Article : Google Scholar : PubMed/NCBI
10	Abraham E, Nick JA, Azam T, Kim SH, Mira JP, Svetkauskaite D, He Q, Zamora M, Murphy J, Park JS, et al: Peripheral blood neutrophil activation patterns are associated with pulmonary inflammatory responses to lipopolysaccharide in humans. J Immunol. 176:7753–7760. 2006. View Article : Google Scholar : PubMed/NCBI
11	Bhatia M and Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 202:145–156. 2004. View Article : Google Scholar : PubMed/NCBI
12	Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, et al: A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 6:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
13	Auron PE: The interleukin 1 receptor: Ligand interactions and signal transduction. Cytokine Growth Factor Rev. 9:221–237. 1998. View Article : Google Scholar
14	Creager MA, Luscher TF, Cosentino F and Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 108:1527–1532. 2003. View Article : Google Scholar : PubMed/NCBI
15	Kagan JC and Medzhitov R: Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell. 125:943–955. 2006. View Article : Google Scholar : PubMed/NCBI
16	Wilson SJ, Leone BA, Anderson D, Manning A and Holgate ST: Immunohistochemical analysis of the activation of NF-kappaB and expression of associated cytokines and adhesion molecules in human models of allergic inflammation. J Pathol. 189:265–272. 1999. View Article : Google Scholar : PubMed/NCBI
17	Richmond A: NF-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002. View Article : Google Scholar : PubMed/NCBI
18	Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol. 18:621–663. 2000. View Article : Google Scholar
19	Senthikumar A and Venkatesalu V: Phytochemical analysis and antibacterial activity of essential oil of Clausena anisata (Wild). Hook. F. ex Benth. Int J Intergrat Biol. 5:116–120. 2009.
20	Ajibesin KK, Ekpo BA, Bala DN, Essien EE and Adesanya SA: Ethnobotanical survey of Akwa Ibom State of Nigeria. J Ethnopharmacol. 115:387–408. 2008. View Article : Google Scholar
21	Hutchings A, Scott AH, Lewis G and Cunningham AB: Zulu Medicinal Plants – An Inventory. 1st edition. University of Natal Press; Pietermaritzburg: 1996
22	Lakshmi V, Prakash D, Raj K, Kapil RS and Popli SP: Monoterpenoid furanocoumarin lactones from Clausena anisata. Phytochemistry. 23:2629–2631. 1984. View Article : Google Scholar
23	Adesina SK and Adewunmi CO: Molluscicidal agents from the root of Clausena anisata. Fitoterapia. 56:289–292. 1985.
24	Makanju OO: Behavioral and anticonvulsant effects of an aqueous extract from the roots of Clausena anisata. Int J Crude Drug Res. 21:29–32. 1983. View Article : Google Scholar
25	Watt JM and Breyer Brandwijk MG: The Medicinal and Poisonous Plants of Southern and Eastern Africa. 2nd edition. E. and S. Livingstone; London: 1962
26	Ganter MT, Roux J, Miyazawa B, Howard M, Frank JA, Su G, Sheppard D, Violette SM, Weinreb PH, Horan GS, et al: Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circ Res. 102:804–812. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kolb M, Margetts PJ, Anthony DC, Pitossi F and Gauldie J: Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 107:1529–1536. 2001. View Article : Google Scholar : PubMed/NCBI
28	Giebelen IA, van Westerloo DJ, LaRosa GJ, de Vos AF and van der Poll T: Local stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the mouse lung. Shock. 28:700–703. 2007.PubMed/NCBI
29	Matthay MA and Zimmerman GA: Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 33:319–327. 2005. View Article : Google Scholar : PubMed/NCBI
30	Scheller J, Chalaris A, Schmidt-Arras D and Rose-John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813:878–888. 2011. View Article : Google Scholar : PubMed/NCBI
31	Mukhopadhyay S, Hoidal JR and Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res. 7:1252006. View Article : Google Scholar : PubMed/NCBI
32	Yang HZ, Wang JP, Mi S, Liu HZ, Cui B, Yan HM, Yan J, Li Z, Liu H, Hua F, et al: TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol. 180:275–292. 2012. View Article : Google Scholar
33	Ghosh S and Hayden MS: New regulators of NF-kappaB in inflammation. Nat Rev Immunol. 8:837–848. 2008. View Article : Google Scholar : PubMed/NCBI
34	Fu Y, Liu B, Zhang N, Liu Z, Liang D, Li F, Cao Y, Feng X, Zhang X and Yang Z: Magnolol inhibits lipopolysaccharide-induced inflammatory response by interfering with TLR4 mediated NF-κB and MAPKs signaling pathways. J Ethnopharmacol. 145:193–199. 2013. View Article : Google Scholar
35	Moine P, McIntyre R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y, Moore EE and Abraham E: NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock. 13:85–91. 2000. View Article : Google Scholar : PubMed/NCBI
36	Goodman RB, Pugin J, Lee JS and Matthay MA: Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 14:523–535. 2003. View Article : Google Scholar : PubMed/NCBI
37	Kuo MY, Liao MF, Chen FL, Li YC, Yang ML, Lin RH and Kuan YH: Luteolin attenuates the pulmonary inflammatory response involves abilities of antioxidation and inhibition of MAPK and NFκB pathways in mice with endotoxin-induced acute lung injury. Food Chem Toxicol. 49:2660–2666. 2011. View Article : Google Scholar : PubMed/NCBI
38	Redington AE, Meng QH, Springall DR, Evans TJ, Créminon C, Maclouf J, Holgate ST, Howarth PH and Polak JM: Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax. 56:351–357. 2001. View Article : Google Scholar : PubMed/NCBI